Nuvectis Pharma (NVCT) Treasury Shares (2021)

Nuvectis Pharma has reported Treasury Shares for 5 years, with the latest figure at $2.9 million in Q1 2026.

• Quarterly Treasury Shares rose 36.55% year-over-year to $2.9 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $2.9 million (up 36.55% YoY) and the FY2025 annual result came in at $2.2 million, up 63.03% from the prior year.
• Treasury Shares climbed to $2.9 million in Q1 2026 per NVCT's latest filing, from $2.2 million in the prior quarter.
• Over five years, Treasury Shares peaked at $2.9 million in Q1 2026 and troughed at $941496.0 in Q4 2023.
• A 4-year average of $1.9 million and a median of $2.1 million in 2025 frame the typical range for Treasury Shares.
• The sharpest annual moves came in 2025 and 2026: Treasury Shares jumped 63.03% in 2025, then soared 36.55% in 2026.
• Over 4 years, Treasury Shares stood at $941496.0 in 2023, then surged by 45.06% to $1.4 million in 2024, then surged by 63.03% to $2.2 million in 2025, then grew by 29.54% to $2.9 million in 2026.
• According to Business Quant data, Treasury Shares over the past three periods registered $2.9 million, $2.2 million, and $2.2 million for Q1 2026, Q4 2025, and Q3 2025 respectively.